Cat. No：GM-C23902
Product：H_CTLA4 Reporter Jurkat Cell Line
Cat. No：GM-C23902
Product：H_CTLA4 Reporter Jurkat Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin+0.75 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+1% FBS +1% P.S
CTLA-4, also known as CD152, is an immunosuppressive receptor expressed constitutively on regulatory T cells (Treg), playing a crucial role in immune response regulation. When CTLA4 is upregulated on the surface of T cells, it binds with higher affinity to CD80 (B7-1) or CD86 (B7-2) compared to the positive co-stimulatory signal of CD28, thereby inducing T cell unresponsiveness. Studies have shown that antibodies and Fc fusion proteins blocking the interaction of CTLA4/CD80 and CD86 have demonstrated promising applications in clinical trials for various cancers.
Current methods for measuring the potential bioactivity of biologics targeting CTLA-4 rely on measuring original human T cell and functional end products, such as cell proliferation, cell surface marker expression, and interferon-gamma (IFNγ) and interleukin-2 (IL-2) production. These assays are challenging to establish in a drug development environment due to reliance on donor primary cells, complex experimental procedures, and substandard assay reagents.
Genomeditech H_CTLA4 Reporter Jurkat Cell Line is a reporter gene cell line that stably expresses the H_CTLA4 gene and Luciferase reporter gene. It is paired with Raji cells, which stably express human CD80 and CD86. When these two cell types are co-cultured, the interaction between CTLA4/CD80 or CD86 inhibits TCR signaling pathway transduction and expression of Luciferase. Addition of CTLA4-blocking antibodies reverses this inhibition, leading to TCR signaling pathway transduction and Luciferase expression, which can be used to assess the efficacy and stability of antibodies and other biologics targeting CTLA-4/CD80 or CD86 interactions.
| CTLA4:CD80:CD86 | ||
| Raji Cell Line | Canine_CD80 aAPC CHO-K1 Cell Line | Canine_CTLA4 Reporter Jurkat Cell Line |
| H_CD80 aAPC CHO-K1 Cell Line | H_CD80 PDL1 aAPC CHO-K1 Cell Line | H_CTLA4 PD-1 Reporter Cell Line |
| Canine_CTLA4 CHO-K1 Cell Line | Cynomolgus_CTLA4 HEK-293 Cell Line | H_CTLA4 CHO-K1 Cell Line |
| H_CTLA4 HEK-293 Cell Line | H_CTLA4 Jurkat Cell Line | |
| Anti-Canine_CTLA4 mIgG2a Antibody(A1mut2) | Anti-CTLA4 hIgG1 Reference Antibody (Ipibio) | Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab) |
| Anti-H_CD80 hIgG1 Antibody(Galiximab) | Anti-H_CTLA-4 hIgG1 Antibody(Ipilimumab) | Anti-mouse CTLA4 mIgG2a Antibody(9D9) |
| Biotinylated Mouse CTLA4 Protein; His-Avi Tag | Mouse CTLA4 Protein; His Tag | |
Cat. No：GM-C23902
Product：H_CTLA4 Reporter Jurkat Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin+0.75 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+1% FBS +1% P.S
CTLA-4, also known as CD152, is an immunosuppressive receptor expressed constitutively on regulatory T cells (Treg), playing a crucial role in immune response regulation. When CTLA4 is upregulated on the surface of T cells, it binds with higher affinity to CD80 (B7-1) or CD86 (B7-2) compared to the positive co-stimulatory signal of CD28, thereby inducing T cell unresponsiveness. Studies have shown that antibodies and Fc fusion proteins blocking the interaction of CTLA4/CD80 and CD86 have demonstrated promising applications in clinical trials for various cancers.
Current methods for measuring the potential bioactivity of biologics targeting CTLA-4 rely on measuring original human T cell and functional end products, such as cell proliferation, cell surface marker expression, and interferon-gamma (IFNγ) and interleukin-2 (IL-2) production. These assays are challenging to establish in a drug development environment due to reliance on donor primary cells, complex experimental procedures, and substandard assay reagents.
Genomeditech H_CTLA4 Reporter Jurkat Cell Line is a reporter gene cell line that stably expresses the H_CTLA4 gene and Luciferase reporter gene. It is paired with Raji cells, which stably express human CD80 and CD86. When these two cell types are co-cultured, the interaction between CTLA4/CD80 or CD86 inhibits TCR signaling pathway transduction and expression of Luciferase. Addition of CTLA4-blocking antibodies reverses this inhibition, leading to TCR signaling pathway transduction and Luciferase expression, which can be used to assess the efficacy and stability of antibodies and other biologics targeting CTLA-4/CD80 or CD86 interactions.
| CTLA4:CD80:CD86 | ||
| Raji Cell Line | Canine_CD80 aAPC CHO-K1 Cell Line | Canine_CTLA4 Reporter Jurkat Cell Line |
| H_CD80 aAPC CHO-K1 Cell Line | H_CD80 PDL1 aAPC CHO-K1 Cell Line | H_CTLA4 PD-1 Reporter Cell Line |
| Canine_CTLA4 CHO-K1 Cell Line | Cynomolgus_CTLA4 HEK-293 Cell Line | H_CTLA4 CHO-K1 Cell Line |
| H_CTLA4 HEK-293 Cell Line | H_CTLA4 Jurkat Cell Line | |
| Anti-Canine_CTLA4 mIgG2a Antibody(A1mut2) | Anti-CTLA4 hIgG1 Reference Antibody (Ipibio) | Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab) |
| Anti-H_CD80 hIgG1 Antibody(Galiximab) | Anti-H_CTLA-4 hIgG1 Antibody(Ipilimumab) | Anti-mouse CTLA4 mIgG2a Antibody(9D9) |
| Biotinylated Mouse CTLA4 Protein; His-Avi Tag | Mouse CTLA4 Protein; His Tag | |
